RecruitingPhase 1NCT06930755

Study of NMS-03305293 in Adult Patients With Relapsed Ovarian Cancer

Study of NMS-03305293, a Non-Trapping PARP1-Specific PARP Inhibitor in Relapsed Ovarian Cancer

Sponsor

Nerviano Medical Sciences

Enrollment

24 participants

Start Date

May 13, 2026

Study Type

INTERVENTIONAL

Conditions

Ovarian Cancer

Summary

This is a multicenter, open-label Phase Ia/b study on the safety and efficacy of the combination of NMS-03305293 and topotecan in patients with recurrent ovarian cancer, with dose-limiting toxicity (DLT) escalation. The aim of this study is to determine the safety and tolerability, as well as to evaluate the anti-tumor efficacy and pharmacokinetics of NMS-03305293 in combination with topotecan.

Eligibility

Sex: FEMALEMin Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study tests a new investigational drug called NMS-03305293 for women with relapsed high-grade serous ovarian, fallopian tube, or peritoneal cancer who have not responded well to prior treatments. **You may be eligible if...** - You are an adult woman with high-grade serous ovarian, fallopian tube, or peritoneal cancer confirmed by a tissue sample - Your cancer has progressed after your most recent line of treatment - You have received no more than 5 prior treatment regimens - You have at least one measurable tumor - You are in good enough health (ECOG performance status of 2 or lower) **You may NOT be eligible if...** - You are currently enrolled in another clinical trial - You have a BRCA gene mutation or specific genetic features associated with DNA repair problems - You have been previously treated with PARP inhibitors (a type of targeted therapy) - You are currently receiving other cancer treatments Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.